Evidence map›Paper›PMID 39360175›Full record

ReviewGE Portuguese journal of gastroenterology2024

Portuguese Pancreatic Club Perspective on the Surveillance Strategy for Pancreatic Neuroendocrine Tumours: When and How to Do It?

Miguel Bispo, Susana Marques, Alexandra Fernandes, Eduardo Rodrigues-Pinto, Filipe Vilas-Boas, Ricardo Rio-Tinto, Jacques Devière, Portuguese Pancreatic Club, specialized section of the Portuguese Society of Gastroenterology

Abstract readReview
In one paragraph

Review in GE Portuguese journal of gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Miguel BispoDigestive Oncology Unit, Champalimaud Foundation, Lisbon, Portugal.
Susana MarquesDigestive Oncology Unit, Champalimaud Foundation, Lisbon, Portugal.
Alexandra FernandesDepartment of Gastroenterology, Centro Hospitalar de Leiria, Leiria, Portugal.
Eduardo Rodrigues-PintoDepartment of Gastroenterology, Centro Hospitalar Universitário de São João, Porto, Portugal.
Filipe Vilas-BoasDepartment of Gastroenterology, Centro Hospitalar Universitário de São João, Porto, Portugal.
Ricardo Rio-TintoDigestive Oncology Unit, Champalimaud Foundation, Lisbon, Portugal.
Jacques DevièreDigestive Oncology Unit, Champalimaud Foundation, Lisbon, Portugal.
Portuguese Pancreatic Club, specialized section of the Portuguese Society of Gastroenterology

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pancreatic neuroendocrine tumours (pNETs) are a highly heterogeneous group of tumours with widely variable biological behaviour. The incidence of pNETs has risen exponentially over the last three decades, particularly for asymptomatic small pNETs (≤2 cm), due to the widespread use of cross-sectional imaging in clinical practice. Summary: Current consensus guidelines suggest that incidentally discovered pNETs ≤2 cm can be selectively followed due to the overall low risk of malignancy. Nevertheless, the "watch-and-wait" management strategy for small asymptomatic pNETs is still not widely accepted due to the lack of long-term data on the natural history of these small lesions. Additionally, it is clear that a subset of small pNETs may show malignant behaviour. Key Message: Given the non-negligible risk of malignancy even in small pNETs, it is of the utmost importance to identify other preoperative factors, other than size, that may help to stratify the risk of malignant behaviour and guide clinical management. In this article, the Portuguese Pancreatic Club reviews the importance of risk stratification of pNETs and presents an updated perspective on the surveillance strategy for sporadic well-differentiated pNETs.

Indexed as

EcoendoscopiaEndoscopic ultrasoundIndice proliferativo Ki-67Ki-67 proliferative indexPancreatic neuroendocrine tumourspNETsSurveillanceTumores neuroendócrinos pancreáticosVigilância

Identifiers

PMID39360175
PMCPMC11444664

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.